XENE250117C20000
- 0.00
- 0.000.00%
Xenon Pharmaceuticals Newsroom
J.P. Morgan's Top Healthcare Stocks for 2025
Xenon Pharmaceuticals Participates in a Conference Call With William Blair
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
H.C. Wainwright Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $53
Xenon Pharmaceuticals Analyst Ratings
Promising Efficacy and Tolerability: Douglas Tsao's Buy Rating on Xenon Pharmaceuticals' Azetukalner
Xenon Pharmaceuticals Reveals Promising Epilepsy Drug Data
Xenon New Long-Term Azetukalner Data Shows Sustained Monthly Reductions In Seizure Frequency Maintained At 85% At OLE Study Month 36; Approximately 1/3 Patients On Drug For At Least 36-Months Achieved Seizure Freedom For A Period Of 1-Year Or Longer
Express News | Xenon Pharmaceuticals Inc - Ole Data Shows Sustained Monthly Reduction in Seizure Frequency, Consistent Ae Safety Profile
Xenon Pharmaceuticals Named a Best Idea for 2025 at TD Cowen
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Xenon To Present Long-Term Azetukalner Data At AES 2024
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Xenon to Present at Upcoming Investor Conferences
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $56
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
TD Cowen Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating